A Walk with Lu-177 PSMA: How Close we Have Reached from Bench to Bedside?

References

• Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends-an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27. doi:10.1158/1055-9965.EPI-15-0578.
   PubMed Web of Science ®Google Scholar
• Jain S, Saxena S, Kumar A. Epidemiology of prostate cancer in India. Meta Gene. 2014;2:596–605. doi:10.1016/j.mgene.2014.07.007.
   PubMedGoogle Scholar
• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. doi:10.3322/caac.20073.
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12. doi:10.1056/NEJMoa040720.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97. doi:10.1056/NEJMoa1207506.
   PubMed Web of Science ®Google Scholar
• De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005. doi:10.1056/NEJMoa1014618.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: arandomised open-label trial. Lancet. 2010;376(9747):1147–54. doi:10.1016/S0140-6736(10)61389-X.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22. doi:10.1056/NEJMoa1001294.
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23. doi:10.1056/NEJMoa1213755.
   PubMed Web of Science ®Google Scholar
• Taghizadeh H, Marhold M, Tomasich E, Udovica S, Merchant A, Krainer M. Immune checkpoint inhibitors in mCRPC – rationales, challenges and perspectives. Oncoimmunology. 2019;8(11):e1644109doi:10.1080/2162402X.2019.1644109.
   PubMed Web of Science ®Google Scholar
• Palekar-Shanbhag P, Jog SV, Chogale MM, Gaikwad SS. Theranostics for cancer therapy. Curr Drug Deliv. 2013;10(3):357–62. doi:10.2174/1567201811310030013.
   PubMed Web of Science ®Google Scholar
• Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52(4):637–40. doi:10.1016/S0090-4295(98)00278-7.
   PubMed Web of Science ®Google Scholar
• Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81–5.
   PubMed Web of Science ®Google Scholar
• Troyer JK, Beckett ML, Wright GL. Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer. 1995;62(5):552–8. doi:10.1002/ijc.2910620511.
   PubMed Web of Science ®Google Scholar
• Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor associated neovasculature. Cancer Res. 1999;59(13):3192–8.
   PubMed Web of Science ®Google Scholar
• Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB, et al. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res. 1999;5(10):2674–81.
   PubMed Web of Science ®Google Scholar
• Nomura N, Pastorino S, Jiang P, Lambert G, Crawford JR, Gymnopoulos M, et al. Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases. Cancer Cell Int. 2014;14(1):26. doi:10.1186/1475-2867-14-26.
   PubMedGoogle Scholar
• Gupta M, Choudhury PS, Gupta G, Gandhi J. Metastasis in urothelial carcinoma mimicking prostate cancer metastasis in Ga-68 prostate-specific membrane antigen positron emission tomography-computed tomography in a case of synchronous malignancy. Indian J Nucl Med. 2016;31(3):222–4. doi:10.4103/0972-3919.183615.
   PubMed Web of Science ®Google Scholar
• Kahn D, Williams RD, Manyak MJ, Haseman MK, Seldin DW, Libertino JA, et al. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. J Urol. 1998;159(6):2041–6.
   PubMedGoogle Scholar
• Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, et al. Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2013;19(18):5182–91. doi:10.1158/1078-0432.CCR-13-0231.
   PubMed Web of Science ®Google Scholar
• Will L, Sonni I, Kopka K, Kratochwil C, Giesel FL, Haberkorn U. Radiolabeled prostate-specific membrane antigen small-molecule inhibitors. Q J Nucl Med Mol Imaging. 2017;61(2):168–80. doi:10.23736/S1824-4785.17.02977-6.
   PubMed Web of Science ®Google Scholar
• Rowe SP, Gorin MA, Pomper MG. Imaging of prostate-specific membrane antigen with small-molecule PET radiotracers: from the bench to advanced clinical applications. Annu Rev Med. 2019;70:461–77. doi:10.1146/annurev-med-062117-073027.
   PubMed Web of Science ®Google Scholar
• Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56(5):668–74. doi:10.2967/jnumed.115.154153.
   PubMed Web of Science ®Google Scholar
• Gupta M, Choudhury PS, Rawal S, Goel HC, Talwar V, Singh A, et al. Initial risk stratification and staging in prostate cancer with prostatic-specific membrane antigen positron emission tomography/computed tomography: a first-stop-shop. World J Nucl Med. 2018;17(4):261–9. doi:10.4103/wjnm.WJNM_79_17.
   PubMedGoogle Scholar
• Benešová M, Schäfer M, Bauder-Wüst U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56(6):914–20. doi:10.2967/jnumed.114.147413.
   PubMed Web of Science ®Google Scholar
• Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, et al. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43(1):42–51. doi:10.1007/s00259-015-3174-7.
   PubMed Web of Science ®Google Scholar
• Fendler WP, Reinhardt S, Ilhan H, Delker A, Böning G, Gildehaus FJ, et al. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget. 2017;8(2):3581–90. doi:10.18632/oncotarget.12240.
   PubMedGoogle Scholar
• Ahmadzadehfar H, Rahbar K, Kürpig S, Bögemann M, Claesener M, Eppard E, et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015;5(1):114 doi:10.1186/s13550-015-0114-2.
   PubMedGoogle Scholar
• Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58(1):85–90. doi:10.2967/jnumed.116.183194.
   PubMed Web of Science ®Google Scholar
• Calopedos RJS, Chalasani V, Asher R, Emmett L, Woo HH. Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2017;20(3):352–60. doi:10.1038/pcan.2017.23.
   PubMed Web of Science ®Google Scholar
• Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825–33. doi:10.1016/S1470-2045(18)30198-0.
   PubMed Web of Science ®Google Scholar
• Violet J, Sandhu S, Iravani A, Ferdinandus J, Thang SP, Kong G, et al. Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 (177Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer. J Nucl Med. 2019;61(6):857–865. doi:10.2967/jnumed.119.236414.
   PubMed Web of Science ®Google Scholar
• Aghdam RA, Amoui M, Ghodsirad M, Khoshbakht S, Mofid B, Kaghazchi F, et al. Efficacy and safety of 177Lutetium-prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer patients: first experience in West Asia – a prospective study. World J Nucl Med. 2019;18(3):258–65. doi:10.4103/wjnm.WJNM_66_18.
   PubMedGoogle Scholar
• Gupta M, Choudhury PS, Rawal S, Karthikeyan G, Talwar V, Dutta KD, et al. Safety profile and therapeutic efficacy of one cycle of Lu177-PSMA in end-stage metastatic castration-resistant prostate cancer patients with low performance status. Nucl Med Mol Imaging. 2019;53(6):423–31. doi:10.1007/s13139-019-00624-8.
   PubMed Web of Science ®Google Scholar
• Rathke H, Giesel FL, Flechsig P, Kopka K, Mier W, Hohenfellner M, et al. Repeated 177Lu-labeled PSMA-617 radioligand therapy using treatment activities of Up to 9.3 GBq. J Nucl Med. 2018;59(3):459–65. doi:10.2967/jnumed.117.194209.
   PubMed Web of Science ®Google Scholar
• Seifert R, Kessel K, Schlack K, Weckesser M, Bögemann M, Rahbar K. Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis. Eur J Nucl Med Mol Imaging. 2020;47(9):2106–12. doi:10.1007/s00259-020-04703-3.
   PubMed Web of Science ®Google Scholar
• Calais J, Fendler WP, Eiber M, Lassmann M, Dahlbom M, Esfandiari R, et al. RESIST-PC phase 2 trial: 177Lu-PSMA-617 radionuclide therapy for metastatic castrate-resistant prostate cancer. JCO. 2019;37(15_suppl):5028. doi:10.1200/JCO.2019.37.15_suppl.5028.
   Google Scholar
• Rasul S, Hacker M, Kretschmer-Chott E, Leisser A, Grubmüller B, Kramer G, et al. Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks. Eur J Nucl Med Mol Imaging. 2020;47(3):713–20. doi:10.1007/s00259-019-04584-1.
   PubMed Web of Science ®Google Scholar
• Sartor AO, Morris MJ, Krause BJ. VISION: an international, prospective, open-label, multicenter, randomized phase 3 study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2019;37(15_suppl):TPS5099–TPS5099. doi:10.1200/JCO.2019.37.15_suppl.TPS5099.
   Web of Science ®Google Scholar
• Hofman MS, Emmett L, Violet J, Y Zhang A, Lawrence NJ, Stockler M, et al. TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603). BJU Int. 2019;124(Suppl 1):5–13. doi:10.1111/bju.14876.
   PubMedGoogle Scholar
• Hofman MS, Emmett L, Sandhu SK, Iravani A, Joshua AM, Goh JC, et al. TheraP: a randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: initial results (ANZUP protocol 1603). J Clin Oncol. 2020;38(15_suppl):5500–5500. doi:10.1200/JCO.2020.38.15_suppl.5500.
   Web of Science ®Google Scholar
• Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone (ARROW). May 7, 2019. [cited 2020 Feb 21]; Available from: https://clinicaltrials.gov/ct2/show/NCT03939689.
   Google Scholar
• 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer (LuPARP). March 14, 2019. [cited 2019 July 19]; Available from: https://clinicaltrials.gov/ct2/show/NCT03874884.
   Google Scholar
• PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr) (PRINCE). September 5, 2018. [cited 2019 July 19]; Available from: https://clinicaltrials.gov/ct2/show/NCT03658447.
   Google Scholar
• 177Lu − J591 and 177Lu − PSMA − 617 Combination for mCRPC. June 4, 2018. [cited 2019 July 30]; Available from: https://clinicaltrials.gov/ct2/show/NCT03545165.
   Google Scholar